- Renowned Clinical Authorities to Advise on Development of New Drug
Candidate to Treat Autoimmune Disease -
SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has appointed the first five members of its Scientific Advisory Board for A-623, a peptide fusion protein licensed from Amgen in December 2007 for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The scientific advisory board will include Jill Buyon, M.D., Betty Diamond, M.D., Kenneth Kalunian, M.D., David Wofsy, M.D., and Debra Zack, M.D., Ph.D.
"We are pleased to have recruited such an outstanding team of
internationally recognized experts in the field of autoimmune disease,"
said Paul F. Truex, President and Chief Executive Officer of Anthera
Pharmaceuticals, Inc. "All have made significant contributions to the
scientific understanding of lupus. The extraordinary magnitude of research
and clinical expertise assembled on this board will be invaluable as we
advance our clinical development programs for A-623."
-- Jill Buyon, M.D. is Professor of Medicine, New York University School
of Medicine and Vice Chairman of the Department of Rheumatology at NYU
Hospital for Joint Diseases.
-- Betty Diamond, M.D. is Head of The Center for Autoimmune and
Musculoskeletal Disease at the Feinstein Institute for Medical
Research and is on the faculty at Albert Einstein College of Medicine.
-- Kenneth Kalunian, M.D. is Professor of Medicine in the Division of
Rheumatology at the University of California, San Diego School of
-- David Wofsy, M.D. is Professor of Medicine and Microbiology/Immunology
at the University of California, San Francisco.
-- Debra Zack, M.D., Ph.D. is the Executive Director in Inflammation
|SOURCE Anthera Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved